BCIQ Profiles

Company Profile ReportTarget Profile Report
0824 Atavistik ECP
BioCentury & Getty Images

Emerging Company Profile

Atavistik: Identifying allosteric modulators of metabolic proteins

Emerging Company Profile: Utah spinout launching with $60M to identify allosteric regulatory sites on metabolic targets

TCG-built Atavistik Bio is launching with a $60M series A round to identify allosteric regulatory sites on disease-causing proteins.

Aug 24, 2021 | 8:52 PM GMT

Launching with a $60 million series A round, Atavistik is advancing an allosteric modulator discovery platform built on technology developed by Jared

Read the full 742 word article

How to gain access

Continue reading with a
two-week free trial.